HUP0402118A2 - Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease - Google Patents

Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease

Info

Publication number
HUP0402118A2
HUP0402118A2 HU0402118A HUP0402118A HUP0402118A2 HU P0402118 A2 HUP0402118 A2 HU P0402118A2 HU 0402118 A HU0402118 A HU 0402118A HU P0402118 A HUP0402118 A HU P0402118A HU P0402118 A2 HUP0402118 A2 HU P0402118A2
Authority
HU
Hungary
Prior art keywords
propionyl
disease
carnitine
peyronie
treatment
Prior art date
Application number
HU0402118A
Other languages
Hungarian (hu)
Inventor
Aleardo Koverech
Giorgio Cavallini
Giulio Biagiotti
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HUP0402118A2 publication Critical patent/HUP0402118A2/en
Publication of HUP0402118A3 publication Critical patent/HUP0402118A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány tárgya propionil-L-karnitin vagy gyógyászatilagelfogadható sója alkalmazása Peyronie-betegség kezelésére használhatógyógyszer előállítására a betegség különféle fázisai esetén, különösenaz előrehaladott fázisban és a szokásos kezelésekkel szembenrezisztens formáknál. A gyógyszer alkalmas orális, intramuszkuláris,intravénás vagy plakkba történő beadásra. A találmány tárgya továbbáegy hatóanyag- kombináció Peyronie-betegség kezelésére, közelebbrőlverapamil és propionil-L-karnitin vagy gyógyászatilag elfogadható sójakombinációja. A propionil-L-karnitin hatásosabbnak mutatkozott azismert hatóanyagoknál és kevesebb mellékhatást fejt ki. ÓThe subject of the invention is the use of propionyl-L-carnitine or its pharmaceutically acceptable salt for the preparation of a medicine for the treatment of Peyronie's disease in various phases of the disease, especially in the advanced phase and in forms resistant to conventional treatments. The drug is suitable for oral, intramuscular, intravenous or plaque administration. The subject of the invention is also a combination of active ingredients for the treatment of Peyronie's disease, more specifically a combination of verapamil and propionyl-L-carnitine or a pharmaceutically acceptable salt thereof. Propionyl-L-carnitine proved to be more effective than known active ingredients and has fewer side effects. HE

HU0402118A 2001-11-26 2002-11-26 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease HUP0402118A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000695A ITRM20010695A1 (en) 2001-11-26 2001-11-26 USE OF PROPIONIL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF
PCT/IT2002/000745 WO2003045373A1 (en) 2001-11-26 2002-11-26 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease

Publications (2)

Publication Number Publication Date
HUP0402118A2 true HUP0402118A2 (en) 2005-02-28
HUP0402118A3 HUP0402118A3 (en) 2012-09-28

Family

ID=11455896

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402118A HUP0402118A3 (en) 2001-11-26 2002-11-26 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease

Country Status (17)

Country Link
US (1) US20050038044A1 (en)
EP (1) EP1448184B1 (en)
JP (1) JP4370168B2 (en)
KR (1) KR100923139B1 (en)
AT (1) ATE323481T1 (en)
AU (1) AU2002358991A1 (en)
CA (1) CA2466135C (en)
CY (1) CY1105347T1 (en)
DE (1) DE60210804T2 (en)
DK (1) DK1448184T3 (en)
ES (1) ES2261772T3 (en)
HU (1) HUP0402118A3 (en)
IT (1) ITRM20010695A1 (en)
MX (1) MXPA04004900A (en)
PL (1) PL209317B1 (en)
PT (1) PT1448184E (en)
WO (1) WO2003045373A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2658307C2 (en) * 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkane compounds, process for their preparation and their use as medicaments
WO1983001782A1 (en) * 1981-11-18 1983-05-26 Merk, Werner Fat refining
US5038633A (en) * 1989-09-28 1991-08-13 Kabushiki Kaisha Kobe Seiko Sho Transmission for mini shovel car
IT1283967B1 (en) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti USE OF L-CARNITINE OR L-CARNITINE DERIVATIVES AND ANTIOXIDANTS IN THE PREVENTION AND TREATMENT OF PATHOLOGIES ARISING FROM OXIDATIVE DAMAGES
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
IT1290600B1 (en) * 1997-04-30 1998-12-10 Sigma Tau Ind Farmaceuti SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION INCLUDING L-CARNITINE AND ALKANOYL L-CARNITINE MAGNESIUM FUMARATE
IT1302858B1 (en) * 1998-11-11 2000-10-10 Sigma Tau Ind Farmaceuti USE OF L-CARNITINE AND ITS ALCANOIL DERIVATIVES FOR THE PREPARATION OF A MEDICATION WITH ANTI-TUMOR ACTIVITY.

Also Published As

Publication number Publication date
DK1448184T3 (en) 2006-08-21
ATE323481T1 (en) 2006-05-15
JP4370168B2 (en) 2009-11-25
EP1448184A1 (en) 2004-08-25
PL371012A1 (en) 2005-06-13
DE60210804D1 (en) 2006-05-24
WO2003045373A1 (en) 2003-06-05
MXPA04004900A (en) 2004-08-02
PT1448184E (en) 2006-07-31
CA2466135C (en) 2011-05-31
ITRM20010695A1 (en) 2003-05-26
KR20040058316A (en) 2004-07-03
JP2005511638A (en) 2005-04-28
KR100923139B1 (en) 2009-10-23
EP1448184B1 (en) 2006-04-19
AU2002358991A1 (en) 2003-06-10
US20050038044A1 (en) 2005-02-17
CY1105347T1 (en) 2010-03-03
CA2466135A1 (en) 2003-06-05
DE60210804T2 (en) 2006-10-19
ES2261772T3 (en) 2006-11-16
PL209317B1 (en) 2011-08-31
HUP0402118A3 (en) 2012-09-28
ITRM20010695A0 (en) 2001-11-26

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
BR0011867A (en) Pharmaceutical preparation of levodopa / carbidopa / entacapone
CY1111088T1 (en) PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY
BR9909672A (en) use of an active medicinal compound in the preparation of a medicament for the treatment of hypertension
JP2002528502A5 (en)
ATE298324T1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
ATE99172T1 (en) USE OF ACETYL-L-CARNITINE IN TREATMENT OF CATARACT, AND PHARMACEUTICAL COMPOSITIONS FOR SUCH TREATMENT.
HUP0402304A2 (en) Deuterated substituted dihydrofuranones and medicaments containing these compounds
KR970061244A (en) Pharmaceutical composition for treating dementia
JP2005508963A5 (en)
HUP0300863A2 (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide, process for producing it and pharmaceutical composition containing it
BRPI0415322A (en) antiretroviral pharmaceutical composition, process for the preparation of an antiretroviral pharmaceutical composition, method for reducing the burden of pill consumption for a patient, method for increasing lamivudine and zidovudine half-life while not affecting nevirapine half-life
HUP0402118A2 (en) Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
HUP0401798A2 (en) Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states
EA200100285A1 (en) ORAL CONCENTRATE SERTRALINA
HUP0402062A2 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them
HUP0400495A2 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
BR0009704A (en) Use of osanetant for the preparation of drugs useful in the treatment of mood disorders
ITRM20020620A1 (en) USE OF CARNITINE FOR THE PREVENTION AND / OR TREATMENT OF DISORDERS CAUSED BY ANDROPAUSE.
EA200300430A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINES AND PSEVDOEDFEDRIN
HUP0300313A2 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
JP2005511638A5 (en)
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
RU2001112719A (en) METHOD FOR TREATMENT OF STENOCARDIA AND ALEXYSTEMIA IN ELDERLY PATIENTS
IT1317079B1 (en) USE OF ISOVALERIL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished